Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T22:43:41.104Z.
Consensus retrieved: 2026-10-06T17:52:53.108Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T22:43:41.104Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 3426d5a31c39f39b03255f489736213a5d3ef01d64930d1418f7917ed6abe5c1
Forward PE Ratio (N/A) = Dated Quote Price ($18.31) / Consensus Forward EPS ($-7.21)
FORWARD PE RATIO
N/A
Vor Biopharma Inc.
Market Cap
$992.14M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Vor Biopharma Inc. (VOR) | $992.14M | N/A |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $996.65M | N/A |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $998.69M | N/A |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $982.46M | N/A |
| MeiraGTx Holdings plc (MGTX)vs › | $981.66M | 35.33 |
| Immatics N.V. (IMTX)vs › | $1.01B | N/A |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $978.09M | N/A |
| Pacira BioSciences, Inc. (PCRX)vs › | $973.93M | N/A |
| Castle Biosciences, Inc. (CSTL)vs › | $1.02B | N/A |
| Janux Therapeutics, Inc. (JANX)vs › | $1.02B | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $18.31, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-7.21 | $-8.05 – $-6.63 | 4 | n/m |
| 2027-12-31 | $-3.60 | $-3.83 – $-3.07 | 6 | n/m |
| 2028-12-31 | $-3.92 | $-5.86 – $-2.61 | 8 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
